Get the Stockscreener App
15.45
0.68%
-0.10
Inhibrx Biosciences Inc stock is traded at $15.45, with a volume of 13,209.
It is down -0.68% in the last 24 hours and up +4.64% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$15.55
Open:
$15.61
24h Volume:
13,209
Relative Volume:
0.14
Market Cap:
$225.10M
Revenue:
$1.80M
Net Income/Loss:
$-241.36M
P/E Ratio:
-3.8148
EPS:
-4.05
Net Cash Flow:
$-197.90M
1W Performance:
-4.07%
1M Performance:
+4.64%
6M Performance:
-54.77%
1Y Performance:
-15.23%
1-Day Range:
$15.24
$15.68
1-Week Range:
$15.24
$16.49
52-Week Range:
$10.80
$39.79
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - StockTitan
James Sabry on industry-shaping changes in innovation and deal-making - BioCentury
Trend Tracker for (INBX) - Stock Traders Daily
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year - Investing.com Australia
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year By Investing.com - Investing.com South Africa
How To Trade (INBX) - Stock Traders Daily
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
INVX underperforms with a -2.86 decrease in share price - US Post News
You might want to take a look at Imunon Inc (IMNN) now - SETE News
Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
A review of IMNN’s current quarter earnings predictions - US Post News
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
IBRX Stock on the Rise: A Promising Investment - The InvestChronicle
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
10% Owner Of Impinj Makes $20.00M Buy - Benzinga
Inmune Bio CFO acquires $49k in company stock By Investing.com - Investing.com Canada
Inmune Bio CEO acquires $98k in company stock - Investing.com
Inmune Bio CFO buys $49k in company stock - Investing.com
Inhibrx CEO buys shares worth over $629k - Investing.com India
Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com Canada
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
How will ImmunityBio Inc’s (IBRX) earnings compare to estimates this quarter? - US Post News
What is IMRX’s price-to-sales ratio telling us about the company’s value? - US Post News
Impinj 10% Owner Trades $20.00M In Company Stock - Benzinga
Take off with ImmunityBio Inc (IBRX): Get ready for trading - SETE News
SEC Form 424B5 filed by INmune Bio Inc. - Quantisnow
Financial Metrics Check: ImmunityBio Inc (IBRX)’s Ratios for Trailing Twelve Months - The Dwinnex
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study - Yahoo Finance
What is Immuneering Corp (IMRX) Stock Return on Shareholders’ Capital? - SETE News
IMRX stock rated a Buy by Needham - Knox Daily
Immuneering’s (IMRX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Inhibrx: The Biotech Spinoff Poised For Big Gains - Forbes
(INBX) Long Term Investment Analysis - Stock Traders Daily
INmune Bio stock dips on $13M securities offering - MSN
Inhibrx Biosciences director buys shares worth nearly $100k - Investing.com
Inhibrx Biosciences director buys shares worth nearly $100k By Investing.com - Investing.com Canada
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) By GuruFocus - Investing.com Canada
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):